Groupon co-founder Eric Lefkofsky just raised another $200 million for his newest company, Tempus 2019

Groupon co-founder Eric Lefkofsky just raised another $200 million for his newest company, Tempus 2019

At the point when sequential business person Eric Lefkofsky grows an organization, he puts the pedal to the metal. At the point when in 2011 his last organization, the Chicago-based coupons site Groupon, raised $950 million from speculators, it was the biggest sum raised by a startup ever. It was a little more than three years of age at the time, and it opened up to the world later that equivalent year. 

Lefkofsky is by all accounts taking a page from a similar playbook for his most current organization, Tempus. The Chicago-based genomic testing and information investigation organization was established somewhat more than three years back, yet it has officially enlisted about 700 representatives and raised more than $500 million — including through another $200 million round that qualities the organization at $3.1 billion. 

As indicated by the Chicago Tribune, that new valuation makes it — as Groupon used to be — a standout amongst Chicago's most exceptionally esteemed secretly held organizations. 

So why all the whine? As the Tribune clarifies it, Tempus has assembled a stage to gather, structure and examine the clinical information that is regularly sloppy in electronic restorative record frameworks. The organization additionally creates genomic information by sequencing understanding DNA and other data in its lab. 

The objective is to help specialists make altered medicines for every individual patient, Lefkofsky tells the paper. 

Up until this point, it has banded together with various disease treatment focuses that are obviously giving Tempus human information from which to learn. Tempus is additionally apparently producing information "in vitro," just like another organization we highlighted as of late called Insitro, a medication advancement startup established by celebrated AI specialist Daphne Koller. With Insitro, it is chipping away at a liver malady treatment attributable to a tie-up with Gilead, which has amassed related human information throughout the years from which Insitro can use to learn. As a reciprocal information source, Insitro is endeavoring to realize what the ailment does in a "dish," at that point decide whether it can utilize what it watches utilizing AI to anticipate what it finds in individuals. 

While's Tempus genomic testing is fixated on malignant growths for the time being, Lefkofsky as of now says that Tempus needs to venture into diabetes and gloom, as well. 

Meanwhile, he discloses to Crain's Chicago Business that Tempus is as of now producing "critical" income. "Our most established accomplices, have, much of the time, presently extended to various subgroups (of malignant growth). What we're doing is working." 

Speculators in the most recent round incorporate Baillie Gifford; Revolution Growth; New Enterprise Associates; assets and records overseen by T. Rowe Price; Novo Holdings; and the speculation the executives organization Franklin Templeton.